Browsing Tag
Chinwe Ukomadu
1 post
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.